Cargando…

Efficacy of tumour-treating fields therapy in recurrent glioblastoma: A narrative review of current evidence

Recurrent Glioblastoma presents a formidable challenge in oncology due to its aggressive nature and limited treatment options. Tumour-Treating Fields (TTFields) Therapy, a novel therapeutic modality, has emerged as a promising approach to address this clinical conundrum. This review synthesizes the...

Descripción completa

Detalles Bibliográficos
Autores principales: Olatunji, Gbolahan, Aderinto, Nicholas, Adefusi, Temiloluwa, Kokori, Emmanuel, Akinmoju, Olumide, Yusuf, Ismaila, Olusakin, Tobi, Muzammil, Muhammad Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695547/
http://dx.doi.org/10.1097/MD.0000000000036421
_version_ 1785153589511979008
author Olatunji, Gbolahan
Aderinto, Nicholas
Adefusi, Temiloluwa
Kokori, Emmanuel
Akinmoju, Olumide
Yusuf, Ismaila
Olusakin, Tobi
Muzammil, Muhammad Ali
author_facet Olatunji, Gbolahan
Aderinto, Nicholas
Adefusi, Temiloluwa
Kokori, Emmanuel
Akinmoju, Olumide
Yusuf, Ismaila
Olusakin, Tobi
Muzammil, Muhammad Ali
author_sort Olatunji, Gbolahan
collection PubMed
description Recurrent Glioblastoma presents a formidable challenge in oncology due to its aggressive nature and limited treatment options. Tumour-Treating Fields (TTFields) Therapy, a novel therapeutic modality, has emerged as a promising approach to address this clinical conundrum. This review synthesizes the current evidence surrounding the efficacy of TTFields Therapy in the context of recurrent Glioblastoma. Diverse academic databases were explored to identify relevant studies published within the last decade. Strategic keyword selection facilitated the inclusion of studies focusing on TTFields Therapy’s efficacy, treatment outcomes, and patient-specific factors. The review reveals a growing body of evidence suggesting the potential clinical benefits of TTFields Therapy for patients with recurrent Glioblastoma. Studies consistently demonstrate its positive impact on overall survival (OS) and progression-free survival (PFS). The therapy’s safety profile remains favorable, with mild to moderate skin reactions being the most commonly reported adverse events. Our analysis highlights the importance of patient selection criteria, with emerging biomarkers such as PTEN mutation status influencing therapy response. Additionally, investigations into combining TTFields Therapy with other treatments, including surgical interventions and novel approaches, offer promising avenues for enhancing therapeutic outcomes. The synthesis of diverse studies underscores the potential of TTFields Therapy as a valuable addition to the armamentarium against recurrent Glioblastoma. The narrative review comprehensively explains the therapy’s mechanisms, clinical benefits, adverse events, and future directions. The insights gathered herein serve as a foundation for clinicians and researchers striving to optimize treatment strategies for patients facing the challenging landscape of recurrent Glioblastoma.
format Online
Article
Text
id pubmed-10695547
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-106955472023-12-05 Efficacy of tumour-treating fields therapy in recurrent glioblastoma: A narrative review of current evidence Olatunji, Gbolahan Aderinto, Nicholas Adefusi, Temiloluwa Kokori, Emmanuel Akinmoju, Olumide Yusuf, Ismaila Olusakin, Tobi Muzammil, Muhammad Ali Medicine (Baltimore) 5300 Recurrent Glioblastoma presents a formidable challenge in oncology due to its aggressive nature and limited treatment options. Tumour-Treating Fields (TTFields) Therapy, a novel therapeutic modality, has emerged as a promising approach to address this clinical conundrum. This review synthesizes the current evidence surrounding the efficacy of TTFields Therapy in the context of recurrent Glioblastoma. Diverse academic databases were explored to identify relevant studies published within the last decade. Strategic keyword selection facilitated the inclusion of studies focusing on TTFields Therapy’s efficacy, treatment outcomes, and patient-specific factors. The review reveals a growing body of evidence suggesting the potential clinical benefits of TTFields Therapy for patients with recurrent Glioblastoma. Studies consistently demonstrate its positive impact on overall survival (OS) and progression-free survival (PFS). The therapy’s safety profile remains favorable, with mild to moderate skin reactions being the most commonly reported adverse events. Our analysis highlights the importance of patient selection criteria, with emerging biomarkers such as PTEN mutation status influencing therapy response. Additionally, investigations into combining TTFields Therapy with other treatments, including surgical interventions and novel approaches, offer promising avenues for enhancing therapeutic outcomes. The synthesis of diverse studies underscores the potential of TTFields Therapy as a valuable addition to the armamentarium against recurrent Glioblastoma. The narrative review comprehensively explains the therapy’s mechanisms, clinical benefits, adverse events, and future directions. The insights gathered herein serve as a foundation for clinicians and researchers striving to optimize treatment strategies for patients facing the challenging landscape of recurrent Glioblastoma. Lippincott Williams & Wilkins 2023-12-01 /pmc/articles/PMC10695547/ http://dx.doi.org/10.1097/MD.0000000000036421 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 5300
Olatunji, Gbolahan
Aderinto, Nicholas
Adefusi, Temiloluwa
Kokori, Emmanuel
Akinmoju, Olumide
Yusuf, Ismaila
Olusakin, Tobi
Muzammil, Muhammad Ali
Efficacy of tumour-treating fields therapy in recurrent glioblastoma: A narrative review of current evidence
title Efficacy of tumour-treating fields therapy in recurrent glioblastoma: A narrative review of current evidence
title_full Efficacy of tumour-treating fields therapy in recurrent glioblastoma: A narrative review of current evidence
title_fullStr Efficacy of tumour-treating fields therapy in recurrent glioblastoma: A narrative review of current evidence
title_full_unstemmed Efficacy of tumour-treating fields therapy in recurrent glioblastoma: A narrative review of current evidence
title_short Efficacy of tumour-treating fields therapy in recurrent glioblastoma: A narrative review of current evidence
title_sort efficacy of tumour-treating fields therapy in recurrent glioblastoma: a narrative review of current evidence
topic 5300
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695547/
http://dx.doi.org/10.1097/MD.0000000000036421
work_keys_str_mv AT olatunjigbolahan efficacyoftumourtreatingfieldstherapyinrecurrentglioblastomaanarrativereviewofcurrentevidence
AT aderintonicholas efficacyoftumourtreatingfieldstherapyinrecurrentglioblastomaanarrativereviewofcurrentevidence
AT adefusitemiloluwa efficacyoftumourtreatingfieldstherapyinrecurrentglioblastomaanarrativereviewofcurrentevidence
AT kokoriemmanuel efficacyoftumourtreatingfieldstherapyinrecurrentglioblastomaanarrativereviewofcurrentevidence
AT akinmojuolumide efficacyoftumourtreatingfieldstherapyinrecurrentglioblastomaanarrativereviewofcurrentevidence
AT yusufismaila efficacyoftumourtreatingfieldstherapyinrecurrentglioblastomaanarrativereviewofcurrentevidence
AT olusakintobi efficacyoftumourtreatingfieldstherapyinrecurrentglioblastomaanarrativereviewofcurrentevidence
AT muzammilmuhammadali efficacyoftumourtreatingfieldstherapyinrecurrentglioblastomaanarrativereviewofcurrentevidence